文献速递生殖医学产科

铂类化疗对癌症男童后续睾丸功能与生育力的影响

Impacts of platinum-based chemotherapy on subsequent testicular function and fertility in boys with cancer.
PubMed 文献 · Hum Reprod Update · 2020-01-01

本文系统检索了1966年至2020年关于铂类化疗对青春期前人类睾丸及后续睾丸功能和生育力影响的文献。共纳入20项研究(n=13 759名男性),其中关于妊娠和父权的结果不一致,精液分析和激素分析证据有限。总体提示应将铂类化疗纳入评估性腺毒性的临床计算器(如CED)。

要点

  • 铂类化疗对癌症男童后续生育力的影响证据不一致,需纳入临床性腺毒性评估。
  • 妊娠和父权方面,最大对照研究(n=5640)报告风险比0.56(P=0.0023),但其他研究无关联。
  • 精液分析和激素分析证据有限,多数研究未进行铂类亚组分析。

核心结论

  • 铂类化疗应被纳入用于评估儿童癌症治疗性腺毒性的临床计算器(如CED)。
  • 现有证据关于铂类化疗对睾丸功能和生育力的影响存在不一致,需更多高质量研究。

研究设计与样本

  • 系统文献检索,检索PubMed和EMBASE(1966年1月1日至2020年4月5日)。
  • 纳入标准:治疗时年龄≤12岁、暴露于铂类化疗、有生殖功能测量。
  • 共纳入20项研究(n=13 759名男性),其中5项(25%)有对照组,10项(50%)进行了铂类相对性腺毒性亚分析。

主要发现

  • 妊娠和父权:3项研究(n=10 453)报告与铂类负相关,包括最大对照研究(n=5640)风险比=0.56(P=0.0023);另2项研究(n=1781)报告无关联。
  • 精液分析:1项研究(n=129)报告铂类化疗与无精子症相关;另1项研究(n=44)未发现关联;其余未进行铂类亚组分析。
  • 激素分析:关于铂类与FSH升高(生精受损的替代指标)的关联结果矛盾,多数研究基于少量接受铂类化疗的患者。

关键数值与推荐

  • 妊娠和父权:最大对照研究风险比=0.56(P=0.0023),样本n=5640。
  • 精液分析依据世界卫生组织(WHO)标准。

临床怎么用

  • 临床计算器(如CED)应纳入铂类化疗以评估儿童癌症治疗的性腺毒性。
  • 应据此为患者及其照护者提供生育风险咨询,指导生育力保存策略(如睾丸组织冷冻保存)及调整治疗以减少不育风险。

局限性

  • 仅25%的研究包含对照组,50%的研究进行了铂类亚分析。
  • 激素分析多数基于少量接受铂类化疗的患者。
  • 精液分析证据有限,多数研究未进行铂类亚组分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Children with cancer often face infertility as a long-term complication of their treatment. For boys, compromised testicular function is common after chemotherapy and currently there are no well-established options to prevent this damage. Platinum-based agents are used to treat a wide variety of childhood cancers. However, platinum agents are not currently included in the cyclophosphamide equivalent dose (CED), which is used clinically to assess the risks to fertility posed by combination chemotherapy in children with cancer. OBJECTIVE AND RATIONALE: This was a systematic search of the literature designed to determine the evidence for effects of platinum-based cancer treatment on the prepubertal human testis in relation to subsequent testicular function and fertility. SEARCH METHODS: PubMed and EMBASE were searched for articles published in English between 01 January 1966 and 05 April 2020 using search terms including 'cancer treatment', 'chemotherapy', 'human', 'prepubertal', 'testis', 'germ cells', 'testosterone' and related terms. Abstracts were screened and full-text articles were obtained for those that met the three major inclusion criteria (age ≤12 years at treatment, exposure to platinum-based chemotherapeutic and measure of reproductive function). Screening of bibliographies for full-text articles was used to identify additional studies. OUTCOMES: Our initial search identified 1449 articles of which 20 (1.3%) studies (n = 13 759 males) met all inclusion criteria. A control group (healthy individuals or siblings) was included for 5/20 (25%) studies. A total of 10/20 (50%) studies provided sub-analysis of the relative gonadotoxicity of platinum-based agents.The primary outcome measures were: pregnancies and fatherhood; semen analysis; and hormonal function. For pregnancies and fatherhood, three studies (n = 10 453 males) reported negative associations with platinum-agents, including the largest (n = 5640) controlled study (hazard ratio = 0.56, P = 0.0023), whilst two other studies (n = 1781) with platinum sub-analysis reported no association. For semen analysis (based on World Health Organization criteria), platinum-based chemotherapy was associated with azoospermia in one study (n = 129), whilst another (n = 44) found no association and the remainder did not perform platinum-based sub-analysis. For hormone analysis, conflicting results were obtained regarding potential associations between platinum-based agents and elevated FSH (a proxy for impaired spermatogenesis); however, the majority of these studies were based on low numbers of patients receiving platinum-based chemotherapy. WIDER IMPLICATIONS: Overall, these results indicate that platinum-based chemotherapy should be included in clinical calculators, for example CED, used to determine gonadotoxicity for childhood cancer treatment. These findings have important implications for clinicians regarding counselling patients and their carer(s) on fertility risk, guiding requirements for fertility preservation strategies (e.g. testicular tissue cryopreservation) and modification of treatments to reduce or eliminate the risk of infertility in childhood cancer survivors.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Tian En L, Brougham MFH, Wallace WHB, et al. Impacts of platinum-based chemotherapy on subsequent testicular function and fertility in boys with cancer. Hum Reprod Update. 2020. PMID: 32935838. doi:10.1093/humupd/dmaa041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。